共查询到20条相似文献,搜索用时 187 毫秒
1.
目的 探究单核苷酸多态性与肾透明细胞癌易感性的相关性,旨在为准确识别肾透明细胞癌的高危人群提供科学依据。方法 从开源的癌症基因组图谱(TCGA)数据库下载关于肾透明细胞癌单核苷酸多态性(SNP)数据和mRNA表达的原始数据。数据经过整合和标准化后,分析差异表达基因及其表达水平并绘制火山图,将SNP突变频率数据可视化并绘制瀑布图,对突变基因进行基因本体论(GO)和京都基因与基因组百科全书(KEGG)通路富集分析,并可视化生成PPI网络互作网络和重要子模块,筛选与基因表达水平相关的突变基因并绘制生存曲线。结果 筛选出的基因主要富集于细胞外基质结构、ATP酶活性和肌动蛋白纤维的结合等途径,还参与癌症发展相关的多个通路,包括PI3K-Akt、焦点粘连等信号通路;发现PBRM1、SETD2、BAP1这3个基因的突变与相应的mRNA表达水平显著相关(P<0.05);生存分析结果显示,这些基因SNP与生存时间之间没有显著关联(P>0.05)。结论 本研究检测肾透明细胞癌的基因突变并探索其相应的表达可能对预测患者的预后有价值,为进一步探索肾透明细胞癌的分子发病机制和评估患者预后提供了重要的... 相似文献
2.
目的探讨转移性肾透明细胞癌的综合治疗的方法与价值。方法将3例转移性肾透明细胞癌放化疗治疗方案及疗效进行分析探讨。结果3例转移性肾透明细胞癌患者同步放化疗治疗后,存活2年及以上为2例占66.7%,1例治疗后1年内死亡占33.3%。结论转移性肾透明细胞癌仍是一类值得基础和临床探索研究的恶性肿瘤,应加强学习与研究,提高对转移性肾透明细胞癌的认识与治疗。 相似文献
3.
目的探讨肾透明细胞癌中胸苷酸磷酸化酶(TP)和缺氧诱导因子2α(HIF-2α)的表达水平与临床病理指标及预后的关系。方法采用免疫组化技术检测43例肾透明细胞癌组织中TP和HIF-2α的表达。结果 TP和HIF-2α主要表达在肾透明细胞癌肿瘤细胞胞核中。TP在43例肿瘤组织均有表达,TP的表达和肾透明细胞癌的a分期、远处转移和微血管密度有关(P0.05),而与淋巴结转移无关(P0.05)。HIF-2α阳性表达21例,阳性表达率为48.84%。HIF-2α的阳性表达与肾透明细胞癌的远处转移有关(P0.05),而与分期、淋巴结转移和微血管密度无关(P0.05)。TP和HIF-2α表达呈正相关(r=0.837,P0.001)。结论检测TP的表达对肾透明细胞癌患者的预后有指导意义。HIF-2α和TP共同参与了肾透明细胞癌的侵袭和转移。 相似文献
4.
5.
MMP2和TGF-β1在人肾透明细胞癌组织中的表达及其意义 总被引:1,自引:0,他引:1
目的 探讨基质金属蛋白酶2(MMP2)和转化生长因子β1(TGF-β1)在肾透明细胞癌组织中的表达及其意义.方法 应用半定量逆转录-聚合酶链反应(RT-PCR)检测43例肾透明细胞癌患者癌与癌旁组织MMP2和TGF-β1的表达水平.结果 在不同的病理分级和临床分期的43例肾透明细胞癌组织中,MMP2表达水平均显著高于痛旁组织;癌与癌旁MMP2表达的差值随临床分期的升高而呈上升趋势.TGF-β1在肾透明细胞癌组织巾的表达阳性率为32.56%(14/43),而癌旁组织均无表达;TGF-β1表达阳件的.肾透明细胞癌病理分级和临床分期均处于Ⅰ或Ⅱ级(期).结论 MMP2和TGF-β1在肾透明细胞癌组织过度表达参与其浸润生长,侵袭转移等病理过程,对其检测为预后判断提供了帮助. 相似文献
6.
目的对比肾透明细胞癌治疗过程中使用B超检测与CT灌注成像辅助检测治疗的临床疗效。方法选取2010年3月到2011年3月在我院接受治疗的82例被确诊为肾透明细胞癌患者作为治疗的研究对象,对两组患者进行随机分组治疗,在这些肾透明细胞癌患者治疗过程中进行一个常规的治疗用药时,对治疗组患者采用CT灌注成像检测跟踪辅助治疗,对照治疗组则采用B超检测跟踪辅助治疗。根据两组的治疗过程中的跟踪检测数据来判断患者病况将以检测报告作用一个依据用患者进行相对应的治疗。根据两组治疗组的患者治疗情况来判定二种跟踪治疗检测手段的临床检测价值。结果在治疗过程中可以发现,肾透明细胞癌CT灌注成像技术可以得出较好的跟踪检测数据对肾透明细胞癌进行治疗,治疗组的在临床治疗上明显优于对照组。P值均<0.05,均具有统计判定意义。结论 CT灌注成像在对肾透明细胞癌的跟踪治疗上检测结果精确,对于肾透明细胞癌的治疗效果上有着十分重要的医学参考价值。 相似文献
7.
目的探讨miR-1256和miR143基因在人肾透明细胞癌组织中的调控及其临床意义。方法应用RT-PCR的方法从转录水平对36例原发性散发的肾细胞癌和36例正常肾组织中miR-1256和miR143进行检测,采用Western-Blot方法从蛋白质水平来检测miR-1256和miR143基因在肾透明细胞中的调控和表达情况。结果研究结果 miR-1256在肾透明细胞的癌标本组织中的表达明显比对照组织中的低很多,两组差异比较具有统计学意义(P<0.05);miR143在肾透明细胞的癌标本组织中的表达也明显比对照组织低很多,两组差异比较具有统计学意义(P<0.05)。结论 miR-1256和miR143基因的表达情况研究能对肾透明细胞癌的发生和发展有重要临床指导意义。 相似文献
8.
<正>肾癌是源于肾小管或肾集合管上皮细胞的恶性肿瘤。据统计肾癌约占成人恶性肿瘤的2%3%[1],且发病率呈现逐年上升的趋势,但病因尚不清楚。肾癌的主要类型有肾透明细胞癌、肾乳头状腺癌、肾嫌色细胞癌等。其中肾透明细胞癌是一种最常见的肾实质恶性肿瘤,约占肾癌的80%3%[1],且发病率呈现逐年上升的趋势,但病因尚不清楚。肾癌的主要类型有肾透明细胞癌、肾乳头状腺癌、肾嫌色细胞癌等。其中肾透明细胞癌是一种最常见的肾实质恶性肿瘤,约占肾癌的80%85%左右[2],生物学行为极为复杂,对放疗和化疗均不敏感,约有40%以上患者在有效治疗后仍复发[3]。对于其发病机制及治疗的研究迫在眉睫。 相似文献
9.
目的 应用超声造影观察肾内型肾透明细胞癌与尿路上皮癌的血流灌注特点,探讨其鉴别诊断价值。方法收集经病理证实的肾内恶性肿瘤患者105例,其中肾透明细胞癌57例,尿路上皮癌48例。对患者进行常规超声及超声造影检查,比较2组间常规超声下的长径和回声特点;超声造影的增强时间差、增强达峰时间差、增强模式及增强强度;采用受试者工作特征(ROC)曲线分析增强时间差、增强达峰时间差对肾内肿瘤的诊断价值。结果 肾透明细胞癌组最大长径长于尿路上皮癌组(P<0.01),常规超声均以低回声为主;肾透明细胞癌组增强时间差和增强达峰时间差短于尿路上皮癌组(P<0.05)。2组造影后肿物增强模式均以快进快退为主,2组增强强度差异有统计学意义(P<0.01)。ROC曲线提示增强时间差鉴别诊断肾透明细胞癌与尿路上皮癌的效能优于增强达峰时间差(Z=3.600,P<0.01)。结论 超声造影可以作为常规超声在鉴别肾透明细胞癌和尿路上皮癌的重要补充。 相似文献
10.
目的:探讨在肾透明细胞癌中丝裂原活化蛋白激酶P38(p38MAPK,p38)和c-Jun氨基末端激酶(c-Jun N-terminal kinase,JNK)的表达及其临床意义.方法:采用免疫组织化学方法,研究癌旁正常组织(20例)、肾透明细胞癌组织(52例)中P38和JNK蛋白的表达情况.结果:P38和JNK在肾透明细胞癌中的阳性表达率分别为75.00%和63.49%,而在癌旁正常组织中阳性表达率分别为30.00%和25.00%.P38和JNK在肾透明细胞癌中的阳性表达率明显高于癌旁正常组织(P<0.01和P<0.05),与肿瘤的临床TNM分期、病理分化相关(P<0.05),而与患者性别、年龄无关(P>0.05).对肾透明细胞癌中P38和JNK进行相关性分析呈正相关(r=0.484,P<0.001).结论:在肾透明细胞癌中P38和JNK的表达高于癌旁组织,且与肿瘤的临床TNM分期、病理分化相关,提示P38和JNK与肾组织癌变、侵袭和转移过程有关. 相似文献
11.
Ma J Jin H Wang H Yuan J Bao T Jiang X Zhang W Zhao H Yao L 《Biological & pharmaceutical bulletin》2008,31(7):1316-1320
Clear cell renal cell carcinoma (CCRCC) is the most common pathological type of renal cell carcinoma and the main cause of renal carcinoma mortality. NDRG2, a new member of the N-Myc downstream-regulated gene (NDRG) family, is a focus for study at present. Up to now, its expression and function in carcinoma remain unclear. The aim of this study was to investigate its expression in CCRCC tissues and several renal carcinoma cell lines. The expression of NDRG2 was evaluated in renal cell carcinoma cell lines, tumor and adjacent non-tumor tissues from same clear cell renal cell carcinoma patients, by using immunohistochemistry, immunofluorescence, RT-PCR and Western blot. By immunohistochemistry and immunofluorescence we found that NDRG2 was predominantly located in the cytoplasm and membrane of renal carcinoma cancer cells, and the positive rate of NDRG2 in renal carcinoma specimens was 30.3% (40/132), which is significantly lower than 91.67% (121/132) in normal renal tissues (p<0.01). The average staining score in normal renal tissues was significantly higher than renal carcinoma (6.12+/-1.84 versus 2.65+/-1.23, p<0.01). Moreover, NDRG2 mRNA and protein were down-regulated in 6 fresh CCRCC tissues compared with their adjacent noncancerous tissues and normal tissues. Its expression was also lower in the human CCRCC-derived cell lines A-498 and 786-O than in the human proximal tubular cell lines HK-2 and HKC. These results indicated that NDRG2 might play an important role in the carcinogenesis and development of CCRCC and may function as a tumor suppressor in CCRCC. 相似文献
12.
摘要: 目的 探讨脂肪酸结合蛋白5 (FABP5) 基因在肾透明细胞癌中的表达及预后意义。方法 提取Oncomine 和GEO数据库中有关FABP5的信息并进行表达情况分析, 通过DAVID数据库对差异基因进行功能注释, 采用 GEPIA进行预后分析。结果 Oncomine数据库中共找到445项FABP5在不同肿瘤类型中的研究数据集, 表达差异有统计学意义的结果中表达增高的有32项 (肾癌5项), 表达降低的有24项 (肾癌0项)。肾癌中有4项涉及肾透明细胞癌和正常组织中FABP5的表达研究数据集。综合比较这4项数据集发现, FABP5在肾透明细胞癌中的表达量高于正常组织 (P<0.05)。GEO数据库中GSE66271芯片数据分析结果发现差异基因FABP5在肾透明细胞癌中的表达量显著高于正常组织 (P<0.01)。DAVID功能分析发现这些差异基因主要集中于影响细胞的转运蛋白活性和蛋白质的消化和吸收代谢功能。使用GEPIA分析来自TCGA数据库和GTEx项目的516例患者预后发现FABP5高表达的患者总体死亡率较高, 低表达FABP5的患者预后较好 (P=0.001 1)。结论 FABP5在肾透明细胞癌组织中呈现高表达,并与肾透明细胞癌预后差相关, 其有望成为抗肾透明细胞癌药物的重要治疗靶点。 相似文献
13.
目的提高囊性肾癌的诊治水平。方法回顾性分析我院2002~2011年间诊治的11例囊性肾癌患者临床资料,分析其影像学特点、病理检查结果及预后情况。结果 11例患者中10例行肾癌根治术,1例行肾部分切除术。囊腔直径2.8~8.5cm。2例术中行冰冻病理:肾透明细胞癌2例,术后病理诊断:肾透明细胞癌9例,颗粒细胞癌2例。病理学分型:5例为单房囊性肾癌,2例为多房囊性肾癌,肾囊肿恶变型2例,肾癌囊性坏死2例。11例均获随访,随访时间3-60个月,平均28.6个月,无瘤存活10例,1例因其他原因死亡。结论囊性肾癌诊断较为困难,应结合术前影像学检查、术中冷冻切片以及术后病理检查结果确诊,以免漏诊,囊性肾癌同肾癌一样采用肾癌根治术或肾部分切除术治疗,效果满意,预后佳。 相似文献
14.
徐美 《中国现代药物应用》2021,(2)
目的探讨腹部超声造影在鉴别低回声肾血管平滑肌脂肪瘤与肾透明细胞癌中的应用价值。方法67例经手术病理证实的肾肿块患者作为研究对象,均行腹部超声造影。分析所有患者的手术病理结果及超声造影表现,比较肾透明细胞癌与低回声肾血管平滑肌脂肪瘤患者的超声造影增强模式及超声造影诊断的准确性。结果67例肾肿块患者中,51例为肾透明细胞癌,16例为低回声肾血管平滑肌脂肪瘤。其中低回声肾血管平滑肌脂肪瘤内部均质,血管发育畸形,微血管较少,血流阻力高,且为厚壁血管,流速缓慢。超声造影显示,肾透明细胞癌以快进快退为主,占比47.06%;低回声肾血管平滑肌脂肪瘤以快进慢退为主,占比75.00%。肾透明细胞癌快进快退占比47.06%高于低回声肾血管平滑肌脂肪瘤的0,而快进慢退占比23.53%低于低回声肾血管平滑肌脂肪瘤的75.00%,差异有统计学意义(P<0.05)。两者同进同退、慢进快退和慢进慢退占比比较差异无统计学意义(P>0.05)。超声造影诊断肾透明细胞癌的准确率为92.16%,与低回声肾血管平滑肌脂肪瘤的93.75%比较,差异无统计学意义(P>0.05)。结论腹部超声造影在鉴别低回声肾血管平滑肌脂肪瘤与肾透明细胞癌中具有重要意义,可为临床治疗提供依据。 相似文献
15.
目的探讨超声造影在肾透明细胞癌诊断中的应用价值。方法对病理结果为肾透明细胞癌的42例患者的超声造影结果进行列顾性分析,对肾透明细胞癌超声造影模式进行分型,并与病理分化程度进行对照研究。结果肾透明细胞癌超声造影模式分四型:Ⅰ型:快进快出型14例,Ⅱ型:快进慢出型9例,Ⅲ型:同进同出型9洲,Ⅳ型:慢进慢出型10例,前三型病理组织学表现为分化程度较低,血管成分及血管弹力层纤维丰富,间质成分较少;Ⅳ型病理组织学表现为分化程度较高,间质成分较多,血管成分较少。结论超声造影在肾透明细胞癌的诊断方面有一定的府用价值。 相似文献
16.
目的:探讨埃兹蛋白(Ezrin)和上皮型钙黏蛋白(E-cadherin)在肾透明细胞癌及癌旁正常肾组织中的表达及与肿瘤侵袭、转移的关系.方法:采用免疫组织化学Elivision方法检测45例肾透明细胞癌组织及相应癌旁正常肾组织中Ezrin和E-cadherin的表达情况.结果:45例癌组织Ezrin异常表达率84.4%(38/45),癌旁正常肾组织Ezrin异常表达率40%(18/45),Ezrin在癌组织中的异常表达明显高于癌旁正常肾组织(χ2=18.9,P<0.005);45例癌组织E-cadherin异常表达率73.3%(33/45),癌旁正常肾组织E-cadherin异常表达率35.6%(16/45),E-cadherin在肾透明细胞癌中的异常表达明显高于癌旁正常肾组织(χ3=12.9,P<0.05);两者呈负相关;Ezrin和E-cadherin的表达与淋巴结转移、静脉瘤栓形成有关(P<0.05),与患者年龄、性别、肿瘤大小、病理分期无相关性(P>0.05).结论:Ezrin和E-cadherin与肾透明细胞癌的浸润转移有关,可能作为预测肾癌转移和判断预后的肿瘤标志物. 相似文献
17.
Bukowski RM 《Expert opinion on investigational drugs》2003,12(8):1403-1411
The therapy of renal cell carcinoma remains a challenge for medical oncologists and urologists. During the past 10 years, the molecular abnormalities occurring in various subtypes of renal cancer, such as clear cell renal carcinoma, have been well described. The genetic abnormalities found in clear cell tumours involve chromosome 3p and, additionally, hypermethylation of the von Hippel-Lindau (VHL) gene can be detected. The VHL protein is involved in the angiogenic cascade in non-hypoxic conditions, and the possible role of mutant or hypermethylated VHL protein in promoting angiogenesis is, therefore, of interest. The majority of patients with renal cell carcinoma who receive treatment, such as IL-2 and/or IFN, fail and develop progressive disease. Therapy is therefore inadequate and novel approaches, such as those inhibiting angiogenesis, are of interest. The agent AE-941 (Neovostat trade mark; AEterna) was developed based on the observation that shark cartilage may contain biologically active inhibitors of angiogenesis. A variety of in vitro and in vivo activities of this preparation have been identified. At the molecular level, AE-941 appears to exhibit four different potential mechanisms of action: modulation of matrix proteases; inhibition of vascular endothelial growth factor binding to its receptor; induction of endothelial cell apoptosis; and stimulation of angiostatin production. The antitumour effects of AE-941 are seen in multiple murine models and involve not only effects on primary tumour growth but also on development of metastases. AE-941 is administered orally and has an excellent toxicity profile. Of interest are the findings in patients with renal cell carcinoma. Preliminary trials in this setting have suggested that responses to AE-941 occur and that patients receiving higher doses of this agent may have improved survival. Based on these preliminary data, a large, multi-institutional, randomised, Phase III trial of this agent has now been conducted in patients with metastatic clear cell carcinoma of the kidney. Over 300 patients have been entered into this trial, accrual is complete and results still remain preliminary. The clinical studies in a malignancy such as renal cell carcinoma will provide sentinel and potentially important observations on the clinical effectiveness of this agent. 相似文献
18.
目的:研究基质金属蛋白酶-26和PDZK1在不同分化程度肾透明细胞癌中表达,探讨其与临床发生、发展及预后的意义。方法:通过免疫组织化学(ABC法)对60例不同分化程度肾透明细胞癌组织切片(A组)和20例肾脏良性病变的正常组织切片(B组)检测MMP-26和PDZK1阳性细胞的表达情况。结果:MMP-26在A组的阳性表达率为80%,在B组阳性表达率为50%(P<0.05);PDZK1阳性率A组表达为85.0%,在B组表达为30%(P<0.05)。结论:MMP-26和PDZK1在肾透明细胞癌组织中高表达。 相似文献
19.
《Expert opinion on investigational drugs》2013,22(8):1403-1411
The therapy of renal cell carcinoma remains a challenge for medical oncologists and urologists. During the past 10 years, the molecular abnormalities occurring in various subtypes of renal cancer, such as clear cell renal carcinoma, have been well described. The genetic abnormalities found in clear cell tumours involve chromosome 3p and, additionally, hypermethylation of the von Hippel–Lindau (VHL) gene can be detected. The VHL protein is involved in the angiogenic cascade in non-hypoxic conditions, and the possible role of mutant or hypermethylated VHL protein in promoting angiogenesis is, therefore, of interest. The majority of patients with renal cell carcinoma who receive treatment, such as IL-2 and/or IFN, fail and develop progressive disease. Therapy is therefore inadequate and novel approaches, such as those inhibiting angiogenesis, are of interest. The agent AE-941 (Neovostat?; AEterna) was developed based on the observation that shark cartilage may contain biologically active inhibitors of angiogenesis. A variety of in vitro and in vivo activities of this preparation have been identified. At the molecular level, AE-941 appears to exhibit four different potential mechanisms of action: modulation of matrix proteases; inhibition of vascular endothelial growth factor binding to its receptor; induction of endothelial cell apoptosis; and stimulation of angiostatin production. The antitumour effects of AE-941 are seen in multiple murine models and involve not only effects on primary tumour growth but also on development of metastases. AE-941 is administered orally and has an excellent toxicity profile. Of interest are the findings in patients with renal cell carcinoma. Preliminary trials in this setting have suggested that responses to AE-941 occur and that patients receiving higher doses of this agent may have improved survival. Based on these preliminary data, a large, multi-institutional, randomised, Phase III trial of this agent has now been conducted in patients with metastatic clear cell carcinoma of the kidney. Over 300 patients have been entered into this trial, accrual is complete and results still remain preliminary. The clinical studies in a malignancy such as renal cell carcinoma will provide sentinel and potentially important observations on the clinical effectiveness of this agent. 相似文献